Active, not recruitingPhase 2NCT04624633

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jennifer R. Brown, MD, PhD
Principal Investigator
Jennifer R Brown, MD, PhD, M.D., PhD
Dana-Farber Cancer Institute
Intervention
Acalabrutinib(drug)
Enrollment
29 enrolled
Eligibility
18 years · All sexes
Timeline
2020 – 2028

Study locations (1)

Collaborators

AstraZeneca · TG Therapeutics, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04624633 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials